Bayer (BAYRY) announced its third quarter results yesterday. Revenues of the group recorded a 7% decline to €7.39 billion from €7.94 billion. The company’s earnings per share from continued operations were €0.78, compared to €0.85 in year-ago period.

Bayer operates through three major segments: Healthcare, accounting for 53.24% of total revenues in the third quarter of 2009; CropScience (15.4%), and Material Science (27.5%) with the remaining 4% coming from other items. While Healthcare segment revenues improved marginally by 3.5%, both cropscience and Material Science fell 8.6% and 20%, respectively.

The Healthcare segment recorded revenues of €3.9 billion compared to €3.8 billion in the corresponding period last year. Both the divisions of Healthcare – pharmaceuticals and consumer health contributed to the growth of the Healthcare segment. Bayer’s primary market, Europe – accounting for 39% of its Healthcare revenues – declined 3%, compared to the year-ago period. The other markets of North America,

Imaging3, Inc.

(Public, OTC:IMGG)

A new and radical medical device from Imaging3 Inc. (OTC:IMGG) is ready to set the standard, and revolutionize the way we look at X-ray, MRI and CT scans. Imaging 3 is currently awaiting FDA approval on their DViS (Dominion Volumetric Imaging Scanner). Currently, medical imaging is met with challenges of long waits, lack of space, lack of mobility, and limited uses. However, for the first time ever, health-care workers will be able to instantly view 3D, high-resolution images of virtually any part of the human body. Thus, Imaging 3 looks to change all that. Saving time, saving lives and reducing costs. This technology will “set the standard for the next 10 years.” The following article was composed by StocksHaven Investments alongside Professor Philip Runfeldt, a Behavioral Analyst who has worked with Fortune 500 companies and major Universities throughout

Tiberius Capital II, LLC (”Tiberius”), a value-opportunity fund located in Chicago, announced August 17, 2009 that it is increasing its tender offer price to $1.35 per share, and is extending the expiration date of its tender offer for all MathStar (Pink Sheets: MATH) common shares until 11:59 p.m., New York City time, on August 31, 2009. As of August 14, 2009, approximately 1,430,000 shares of MathStar’s common stock have been tendered and not withdrawn.

ArthroCare Corp. (Pink Sheets: ARTC) August 17, 2009 announced that it has entered into an agreement with One Equity Partners (OEP), the global private equity investment arm of JPMorgan Chase & Co., whereby OEP will purchase $75 million of newly-issued ArthroCare Series A Convertible Preferred Stock. ArthroCare intends to use the proceeds to repay the Company’s existing Credit Agreement and expects to use the remaining portion for general corporate purposes.

Metiscan, Inc. (PINKSHEETS: MTIZ), a holding company focused

Advanced Medical Isotope Corporation (ADMD.PK) develops advanced production systems and processes in the nuclear medicine industry. The Company’s primary focus is on making previously unavailable medical isotopes, such as radioisotopes and stable isotopes, more available to the medical marketplace. In addition, the company leads the way to advanced systems for local product production. The company encourages using less invasive therapeutic processes, liked medical imaging, rather than highly invasive surgical approaches in the diagnosis and treatment of diseases like cancer.

Advanced Medical has the rights to an advanced design compact system. This system is used in a series of medical radioisotopes for the advancement of medical imaging diagnostics. Positron Emission Tomography, also known as PET scanning, or imaging, is a newer diagnostic imaging device. PET scans are used to identify, isolate and target cancerous growths. Using Advanced Medical’s isotopes reduces the process losses that occur when using isotopes produced in a

Roughly 7 million patients worldwide receive interventional cardiovascular therapeutic and diagnostic imaging procedures each year. Approximately 15 percent to 20 percent of all patients undergoing such procedures are at risk of developing Contrast-Induced Nephropathy (CIN), the third leading cause of in-hospital acute renal failure.

Medical device company PLC Systems Inc. (OTCBB: PLCSF) develops cardiac and vascular technologies primarily in the United States. The company today announced it has received full approval from the U.S. Food and Drug Administration (FDA) regarding the company’s RenalGuard System, which was developed for interventional cardiology and radiology patients to eliminate toxins.

The FDA approved the company’s U.S. pivotal trial to study the effectiveness of the RenalGuard System, as well as associated therapies for the prevention of CIN.

“We remain very confident that RenalGuard is a highly promising therapy addressing a large, unmet market need. We are optimistic that the results from the CCM study will provide

Imaging3, Inc. (IMGG.OB), a medical device manufacturer and distributor, has developed a breakthrough technology that utilizes high-resolution photo-flouroscopy to produce three-dimensional medical diagnostic images. With its ability to produce real-time 3D images, Dominion™ can be used to improve any medical procedure where multiple frame references are required to perform surgery on or in the human body.

The Dominion’s patented technology can be applied to a multitude of medical areas including trauma, cardiology, pediatrics, orthopedics, vascular, neuro-vascular, and sports medicine. The real-time 3D images will allow surgeons to plan for less invasive and more precise procedures, which will reduce a patient’s risk and recovery time. In addition to 3D real-time flouroscopic imaging, the Dominion can also emulate other imaging technology, like a CT scan. Along with its high-resolution imaging capabilities, the Dominion is a mobile unit that can fit that is powered by a standard wall outlet and will fit through

ImaRx Therapeutics, Inc. is a biopharmaceutical company engaged in developing and commercializing therapies for vascular disorders in the United States. The company’s operations are focused in two main areas.

First, the company generates revenue from the sale of urokinase, a thrombolytic drug used for the treatment of acute massive pulmonary embolism, or blood clots in the lungs. The company sells urokinase to wholesale distributors under the Kinlytic brand name.

The company uses the revenue from urokinase to fund its SonoLysis clinical program. The company’s research and development efforts are focused on using its proprietary microbubble technology in conjunction with focused ultrasound (SonoLysis) to treat ischemic stroke, as well as other vascular disorders.

Microbubble Technology

Lipid coated microbubbles represent a new class of agents with both diagnostic and therapeutic applications, and ImaRx Therapeutics is on the technological forefront in this area. The company has learned that microbubbles can